A Study to Evaluate the Efficacy of PanCytoVir™ for the Treatment of Non-Hospitalized Patients With COVID-19 Infection

Phase 2 Completed 75 enrolled TrippBio, Inc.

RandomizedParallel-groupSingle-blindTreatment

Summary

This is a randomized, single-center, single-blind, placebo controlled, study to evaluate efficacy of PanCytoVir™ 500 mg twice daily and 1000 mg twice daily for the treatment of non-hospitalized patients with COVID-19 infection.

Timeline

Start: 2022-07-12
Primary completion: 2022-09-07
Completion: 2022-10-08

Outcome

Mixed primary results

paper probenecid 1000 mg group than for placebo (7 days vs. 11 days, respectively; p < 0.0001) PMID 37515194 ↗

paper The primary endpoints of the study were time to first negative SARS-CoV-2 viral test (or viral clearance) PMID 37515194 ↗

paper and the proportion of patients that were symptom-free at day 5. PMID 37515194 ↗

paper All patients reported at least one COVID-19-related symptom on days 3 and 5; PMID 37515194 ↗

Publications

Martin DE, Pandey N, Chavda P, Singh G, Sutariya R, Sancilio F, Tripp RA. Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19. Viruses. 2023 Jul 6;15(7):1508. doi: 10.3390/v15071508.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Probenecid	Small molecule	500 mg	Oral
Subject	Probenecid	Small molecule	1000 mg	Oral